Back to top
more

AngioDynamics (ANGO)

(Real Time Quote from BATS)

$7.45 USD

7.45
210,768

-0.03 (-0.40%)

Updated Jul 24, 2024 12:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Boston Scientific (BSX) Q4 Earnings Miss, Margins Decline

Apart from a drop in Q4 earnings and revenues drop year over year, Boston Scientific (BSX) also registers strong sequential decline in overall financial performance.

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q3

STERIS' (STE) third-quarter fiscal 2021 results reflect strong performance by all three of its reporting segments despite the coronavirus-led economic crisis.

PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) fourth-quarter results benefit from strong segmental performance.

Haemonetics (HAE) Q3 Earnings Top Estimates, Margin Contracts

Haemonetics (HAE) third-quarter fiscal 2021 revenues declined 7.2% year over year to $240.4 million, improving 14.7% sequentially.

IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise

IDEXX (IDXX) registeres strong contribution from its CAG business in the fourth quarter despite pandemic-induced challenges.

McKesson (MCK) Earnings and Revenues Beat Estimates in Q3

McKesson's (MCK) fiscal third-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.

Why You Should Add AngioDynamics (ANGO) to Your Portfolio

Investor confidence is high in AngioDynamics (ANGO) stock, courtesy of its solid prospects.

Onmicell (OMCL) Q4 Earnings Beat Estimates, Margin Contracts

Omnicell's (OMCL) fourth-quarter 2020 revenues rose 0.36% year over year to $249.2 million, improving 16.1% sequentially.

AngioDynamics' (ANGO) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in AngioDynamics (ANGO).

What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?

Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.

AngioDynamics (ANGO) Upgraded to Strong Buy: Here's What You Should Know

AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

AngioDynamics (ANGO) Q2 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q2.

AngioDynamics (ANGO) Surpasses Q2 Earnings and Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 150.00% and 8.01%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?

Cooper Companies (COO) to Post Q4 Earnings: What's in Store?

Cooper Companies' (COO) fiscal fourth-quarter performance is likely to reflect better performance by CVI and CSI.

What's in Store for Patterson Companies' (PDCO) Q2 Earnings?

Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect improvement at Dental segment.

Veeva Systems (VEEV) to Post Q3 Earnings: What's in Store?

Veeva Systems' (VEEV) fiscal third-quarter results are likely to reflect solid show by its segments and robust product portfolio.

AngioDynamics (ANGO) Shows Solid Results from RAPID Database

The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.

HMS Holdings (HMSY) Climbs 7.4% Post In-Line Q3 Earnings

HMS Holdings (HMSY) witnessed revenue growth in COB and PI segments in the third quarter.

AMN Healthcare (AMN) Loses 9.4% Despite Q3 Earnings Beat

AMN Healthcare (AMN) gained from Technology and Workforce Solutions segment in the third quarter.

Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)

Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.

Glaukos (GKOS) Gains 11.8% Despite Reporting Loss in Q3

Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

Luminex (LMNX) Declines 6.6% as Q3 Earnings Miss Estimates

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.

Co-Diagnostics (CODX) to Post Q3 Earnings: What's in Store?

Co-Diagnostics' (CODX) third-quarter results are likely to reflect higher COVID-19 test sales.

Nevro (NVRO) Rallies 1.3% Despite Delivering Loss in Q3

Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.

LHC Group (LHCG) Q3 Earnings and Revenues Beat Estimates

LHC Group's (LHCG) third-quarter results benefit from organic growth in home health as well hospice admissions.